Genetic discrimination

Genetic discrimination is the use of a person's genetic information — a test result, a family history, or a predicted risk — to treat them less favourably in insurance, employment, education, or another domain where the information is not relevant to present ability. The concern predates the ability to sequence a genome cheaply and has produced a patchwork of protections that is strongest where the risk was anticipated and weakest where the information is now actually used.

§What is being protected

The canonical case is a person who learns they carry a pathogenic variant for a late-onset condition — Huntington's disease is the standard example because penetrance is near total and onset is decades away — and is then refused cover or employment on the strength of a prediction about a future they have not yet reached. The harm has two parts. One is the adverse decision. The other is the chilling effect: people who fear the consequences decline testing that would benefit them clinically, which is the effect surveys of at-risk families most consistently find. The same reluctance could extend to predictive tests that are not genetic at all, including the direct-to-consumer panels covered in Consumer blood testing and the multi-cancer screening assays described in Nanoscale diagnostics, where a positive result may reach an underwriter long before it becomes a diagnosis.

Whether genetic information deserves special treatment is contested. The position called genetic exceptionalism holds that it is distinctively sensitive, because it is predictive, shared with relatives, and immutable — the last of which ceases to be true if the editing methods described in Somatic gene therapy mature.¹ Critics note that family history, cholesterol, and an HIV test are also predictive and shared, that most genetic variants carry weak probabilistic information rather than a verdict, and that carving out genetics produces an incoherent privacy regime in which the same fact is protected or unprotected depending on how it was learned.

Sequencing has strengthened the critics' case. Everyone carries variants associated with elevated risk of something. Once whole-genome data is routine, protecting "genetic test results" as a category protects almost nothing, because the discriminating input is the interpretation rather than the sequence — a point that also complicates Polygenic embryo screening, where the output is a probability rather than a diagnosis.

§GINA and its gaps

The US Genetic Information Nondiscrimination Act, enacted in 2008 after more than a decade in Congress, prohibits health insurers from using genetic information in eligibility, premiums, or underwriting, and prohibits employers with fifteen or more employees from using it in hiring, firing, or terms of employment. It also bars employers from requesting or purchasing genetic information, including family medical history, with narrow exceptions.

Its exclusions define the current problem.

Life, disability, and long-term care insurance are not covered. These are the products for which a predictive genetic result is most actuarially useful, and in most US states insurers may lawfully ask for and act on test results. Florida became the first state to close the gap in 2020, barring life, disability, and long-term-care insurers from using genetic test information; a small number of other states have since restricted it in narrower ways.

Manifest disease is not covered. Once a condition has appeared, it is a medical condition rather than genetic information, and GINA no longer applies. Protection is therefore strongest for the asymptomatic and disappears when the risk materialises.

Small employers, the military, and several federal programmes fall outside. The armed services are not bound by GINA, and genetic findings can affect assignment and retention. The exclusion matters more than its size suggests, since military medicine is where several enhancement-adjacent technologies are first adopted, as Enhancement arms race describes.

Selection is untouched. GINA governs what may be done with a living person's genetic information. It says nothing about screening embryos, so the practices covered in Embryo selection fall entirely outside it.

Enforcement has been thin. Regulators have brought a modest number of actions, most concerning employers collecting family medical history in pre-employment physicals or wellness programmes rather than sequencing anyone. The best-known US episode predates the statute: a railway company was found in 2001 to have secretly tested employees who had filed carpal-tunnel claims for a variant it believed predisposed them to the condition, and settled with the federal employment regulator the following year.

Absence of complaints is weak evidence

Low case volume is often cited as showing that genetic discrimination is rare. It is equally consistent with the discrimination being undetectable: an applicant declined cover is rarely told which item in the file was decisive, and an underwriting model that weights a family history does not announce itself.

§Outside the United States

Canada enacted the strongest instrument, a 2017 statute making it a criminal offence to require a genetic test or the disclosure of results as a condition of a contract or service. Its constitutionality was challenged on federalism grounds — insurance is a provincial matter — and the Supreme Court of Canada upheld it as a valid exercise of the criminal law power in 2020.²

The United Kingdom relies on industry self-regulation. Under a code agreed between government and insurers, companies do not ask for predictive genetic test results, with a single exception for Huntington's disease on life cover above a high threshold. It has held for two decades and has no statutory force; the equivalent Australian arrangement was a voluntary industry moratorium, and in 2024 the Australian government announced it would legislate a ban on the use of genetic test results in life insurance underwriting.

The Council of Europe's Oviedo Convention prohibits discrimination on grounds of genetic heritage among its parties, and EU data protection law treats genetic data as a special category requiring an explicit lawful basis. Neither settles the underwriting question directly, and jurisdictions have reached opposite conclusions about whether an insurer may use information the applicant already holds. The same convention supplies the only binding international prohibition on heritable modification, which is why it recurs throughout Governance of human genome editing and the debates over Human germline editing.

§The adverse-selection argument

Insurers make a real argument against prohibition. If applicants may know their genetic risk while insurers may not, the high-risk buy more cover, premiums rise, and the low-risk exit — the classic adverse-selection spiral. Where health cover is universal and publicly funded the argument does not arise, which is why the issue is sharpest in countries with private health and life markets.

The empirical picture is less alarming than the theory. Studies of markets operating under a genetic-testing moratorium have not found the predicted destabilisation, plausibly because the number of people holding a strongly predictive result remains small relative to the pool and because most policies are bought before anyone tests. The distributive stakes also run the other way from those in Access and inequality: here the worry is not that a treatment is unaffordable but that knowing one may need it makes cover unobtainable. Whether that holds as polygenic risk scoring becomes routine is unknown, and it is the version of the question that matters for the next decade.

§Consumer genomics and the data itself

Direct-to-consumer testing put tens of millions of genotypes into private databases governed by terms of service rather than by health-privacy law. Three developments have made that arrangement look fragile.

Law enforcement access came first: the 2018 identification of a serial offender in California through a genealogy database showed that a relative's upload can expose a person who never tested.³ Forensic genetic genealogy is now routine in US investigations, and the individuals whose data enables it did not consent to that use.

Security followed. A large consumer testing company disclosed in 2023 that attackers using credentials stolen elsewhere had accessed millions of profiles through a relative-matching feature — an attack the architecture invited, since the product's purpose is to connect one account's data to another's.

Insolvency completed the set. The same company entered Chapter 11 bankruptcy protection in 2025, and its genetic database was treated as an asset in a court-supervised sale. Several US state attorneys general advised residents to delete their accounts. No US federal law establishes what happens to a genomic database when its custodian fails, and the terms of service under which the data was collected are contracts that a bankruptcy court may modify.

§Where it is heading

Three shifts are already straining the existing framework.

Polygenic scores turn discrimination from a question about rare variants into a question about everyone, since a score can be computed for any trait from a standard genotype array — the mechanism behind Genetic enhancement of cognition and the screening applications marketed under the heading of Designer babies. Insurers do not need a diagnosis to price a risk; a distribution will do.

Population genomic programmes are placing sequence data into national health systems, where the governance question is not whether an insurer may see it but whether a state may.

And the arrival of heritable modification, if it ever occurs, creates a category the statutes do not contemplate: discrimination not on the basis of what a person's genome is but on the basis of what was done to it. Nothing in existing law reaches it, and the parallel debate over Neurorights has begun to raise the same structural question for neural data. Whether the correct response is another category-specific statute, or a general prohibition on unjustified prediction-based discrimination of the kind Disability rights and enhancement scholarship has long argued for, remains unsettled in every jurisdiction that has legislated so far.

§See also

• Mental privacy
• Neurorights
• Polygenic embryo screening
• Access and inequality
• Governance of human genome editing
• Embryo selection
• Disability rights and enhancement
• Designer babies

§References